Dilated Cardiomyopathy

Cardiovascular
4
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Vericel
VericelCAMBRIDGE, MA
2 programs
2
Ixmyelocel-TPhase 21 trial
Ixmyelocel-TPhase 21 trial
Active Trials
NCT00765518Completed40Est. Sep 2012
NCT01020968Completed22Est. Dec 2013
Design Therapeutics
1 program
1
Intracoronary infusion of autologous bone marrow cellsPhase 21 trial
Active Trials
NCT00629096CompletedEst. Dec 2010
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD4063Phase 11 trial
Active Trials
NCT07241104Recruiting31Est. Nov 2027
Bristol Myers Squibb
1 program
protein A immunoadsorptionN/A1 trial
Active Trials
NCT00558584Completed180Est. Apr 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
VericelIxmyelocel-T
VericelIxmyelocel-T
Design TherapeuticsIntracoronary infusion of autologous bone marrow cells
AstraZenecaAZD4063
Bristol Myers Squibbprotein A immunoadsorption

Clinical Trials (5)

Total enrollment: 273 patients across 5 trials

NCT01020968VericelIxmyelocel-T

Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

Start: Dec 2009Est. completion: Dec 201322 patients
Phase 2Completed
NCT00765518VericelIxmyelocel-T

Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

Start: Sep 2008Est. completion: Sep 201240 patients
Phase 2Completed
NCT00629096Design TherapeuticsIntracoronary infusion of autologous bone marrow cells

Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy

Start: Feb 2008Est. completion: Dec 2010
Phase 2Completed
NCT07241104AstraZenecaAZD4063

A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy

Start: Dec 2025Est. completion: Nov 202731 patients
Phase 1Recruiting
NCT00558584Bristol Myers Squibbprotein A immunoadsorption

Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy

Start: Dec 2007Est. completion: Apr 2023180 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
23h ago
From $150K/yr

Associate Regional Clinical Consultant

Johnson & Johnson
Amersfoort, Utrecht, Netherlands
Yesterday

Medical Affairs Sr Scientist- Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
Yesterday
$92K - $148K/yr

Labeling Operations Specialist

Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday

Physician Program Director, Great North

Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday
$132K - $212K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 273 patients
4 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)